Fuse Oncology, a provider of specialized healthcare software solutions, has entered into a strategic agreement with the American College of Radiation Oncology (ACRO) to commercialize ACROPath, ACRO's proprietary clinical pathways platform for radiation oncology. The partnership, announced on March 13, 2025, will see Fuse developing a dedicated application that integrates evidence-based treatment pathways into its existing product line.
The collaboration aims to enhance clinical workflows, increase operational efficiencies, and ultimately improve patient care by standardizing radiation oncology treatment protocols across healthcare settings.
Addressing Critical Needs in Radiation Oncology
"Clinical pathways are more critical than ever, providing a structured approach to ensure safe, consistent patient care while improving access to groundbreaking clinical trials," said Dwight E. Heron, MD, MBA, FACRO, President of ACRO.
The integration will enable radiation oncologists across various practice settings to seamlessly access tools that optimize cancer treatment outcomes. According to ACRO, this reinforces their commitment to supporting radiation oncologists in improving the lives of cancer patients.
Seamless Integration of Evidence-Based Protocols
Under the agreement, Fuse Oncology will incorporate ACRO's proprietary pathways into its suite of products, allowing radiation oncology clinicians to access the latest evidence-based treatment protocols for clinical decision support (CDS) within their daily software tools.
The ACROPath guidelines will be presented in a user-friendly digital format, aggregated and standardized to ensure consistency with best practices. This integration leverages technology to deliver trusted support to clinicians at the point of care, without disrupting established workflows.
Impact on Clinical Practice and Patient Outcomes
Matthew Manning, MD, Radiation Oncologist at Cone Health in Greensboro, N.C., and head of the Fuse Clinical Liaison Board, highlighted the potential impact: "Clinicians will gain real-time decision support based on ACRO's validated pathways with no disruption to their workflow, ensuring consistency with current best practices."
Manning emphasized that the tool fulfills the "five rights" of clinical decision support: "the right information to the right person in the right format through the right channel at the right time." He added that ACROPath integration into Fuse's platform can "reduce care variation and increase quality while improving physician efficiency."
Operational Benefits for Radiation Oncology Clinics
Radiation oncology clinics implementing ACROPath through Fuse's platform can expect several operational benefits:
- Improved operational efficiency
- Enhanced quality control
- Better alignment with national standards
- Streamlined multidisciplinary coordination
- Enhanced outcomes tracking
As clinical care teams utilize Fuse solutions to make informed treatment decisions adhering to proven protocols, patients are expected to experience improved quality of care and better outcomes.
About the Organizations
Fuse Oncology delivers SaaS solutions designed to break down healthcare workflow and data silos, creating a seamless experience for clinicians in radiation oncology. The company places electronic medical record systems at the center of its architecture to eliminate duplicative efforts and enable more efficient oncology care.
The American College of Radiation Oncology (ACRO) is a non-profit medical society founded in 1982 dedicated to supporting radiation oncology professionals. With approximately 1,400 radiation oncology physicians, leaders, and trainees across the United States, ACRO provides opportunities for career development and practice improvement to enhance patient care.
